Therapeutic Asset Ratings

7,021 results matching 1 filter

129,767 assets · 8,707 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Idarubicine Acute Monocytic Leukemia	Chinese PLA General Hospital	P3	BBB (73)
Idarubicine Pediatric AML	Joanna Yi	P3	BBB (73)
Ifosfamide Hodgkins Lymphoma	St. Petersburg State Pavlov Medical University	P3	BBB (73)
LENVATINIB Primary Peritoneal Cavity Cancer	Floor Backes, MD	P3	BBB (73)
MERCAPTOPURINE ANHYDROUS Childhood Acute Lymphoblastic Leukemia	The Children's Hospital of Zhejiang University School of Medicine	P3	BBB (73)
Palbociclib Hormone Receptor-Positive Breast Cancer	BeOne Medicines	P3	BBB (73)
PEGASPARGASE T-Cell Childhood Acute Lymphocytic Leukemia	National Cancer Institute (NCI)	P3	BBB (73)
PEGASPARGASE Childhood Acute Lymphoblastic Leukemia	University of Chicago	P3	BBB (73)
plb1004 Non-Small Cell Lung Carcinoma	Beijing Pearl Biotechnology Limited Liability Company	P3	BBB (73)
Rapamycin Tuberous Sclerosis	Katarzyna Kotulska	P3	BBB (73)
Roluperidone Schizophrenia	Minerva Neurosciences	P3	BBB (73)
Setmelanotide Inherited Obesity	Rhythm Pharmaceuticals, Inc.	P3	BBB (73)
Star-0215 Hereditary Angioedema	Astria Therapeutics, Inc.	P3	BBB (73)
Teta 4Hcl Wilson Disease	Orphalan	P3	BBB (73)
Ulotaront Schizophrenia	Otsuka Pharmaceutical Co., Ltd.	P3	BBB (73)
Vebreltinib Non-Small Cell Lung Carcinoma	Second Affiliated Hospital of Nanchang University	P3	BBB (73)
Abiraterone Acetate Metastatic Castration Resistant Prostate Cancer	Jiangsu HengRui Medicine Co., Ltd.	P3	BBB (72)
ASPARAGINASE Childhood Acute Lymphoblastic Leukemia	Therapeutic Advances in Childhood Leukemia Consortium	P3	BBB (72)
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) L1 Childhood Acute Lymphoblastic Leukemia	Therapeutic Advances in Childhood Leukemia Consortium	P3	BBB (72)
ASPARAGINASE ERWINIA CHRYSANTHEMI (RECOMBINANT) Untreated Childhood Acute Myeloid Leukemia and Other Myeloid Malignancies	Joanna Yi	P3	BBB (72)
Blinatumomab Precursor B-Cell Acute Lymphoblastic Leukemia	Amgen	P3	BBB (72)
Blinatumomab B-Lymphoblastic Leukemia/Lymphoma With T(9;22)(Q34.1;Q11.2)	Novartis Pharmaceuticals	P3	BBB (72)
Brentuximab Vedotin Anaplastic Large Cell Lymphoma	Seagen Inc.	P3	BBB (72)
Busulphan Recurrent Adult Diffuse Large Cell Lymphoma	Washington University School of Medicine	P3	BBB (72)
Cagrilintide Obesity Disorder	Novo Nordisk A/S	P3	BBB (72)

Showing 151 to 175 of 7,021 assets

PreviousPage 7 of 281Next